Benoît Ferment

4PUBLICATIONS

18CO-AUTHORS

Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (4)

Sort by Publication Date:

|Jun 19, 2026

CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma.

|Feb 24, 2026

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Sarah Cayla, Lionel Karlin, Jérôme Lambert

|Sep 18, 2025

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Sarah Cayla, Lionel Karlin, Jérôme Lambert

|May 15, 2024

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.

B Ferment, J Lambert, D Caillot

Pageof 1

Frequent Collaborators

Xavier Leleu

Aurore Perrot

Pierre Bories

Jill Corre

Alexis Talbot

Ibrahim Yakoub-Agha

Steven Le Gouill

Salomon Manier

Florent Malard

Jerome Lambert

Frequent Collaborators

Xavier Leleu

Aurore Perrot

Pierre Bories

Jill Corre